In patients, RT plus anti‐CTLA‐4 induced tumor regression, but resistance occurred due to PD‐L1 upregulation; adding anti‐PD‐L1 overcame this resistance and led to durable responses. The gene discussed is CTLA4; the disease is neoplasm.